Separately, Zacks Investment Research raised Trinity Biotech PLC from a sell rating to a hold rating in a report on Wednesday, June 22nd.
Shares of Trinity Biotech PLC (NASDAQ:TRIB) traded up 2.9937% on Wednesday, reaching $6.4989. 526,082 shares of the company were exchanged. The firm has a market capitalization of $149.58 million, a PE ratio of 27.6549 and a beta of 0.97. Trinity Biotech PLC has a 12-month low of $5.76 and a 12-month high of $13.68. The stock’s 50-day moving average is $12.53 and its 200 day moving average is $11.76.
Trinity Biotech PLC (NASDAQ:TRIB) last posted its earnings results on Thursday, July 21st. The company reported $0.09 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.03. The business earned $26.30 million during the quarter, compared to analyst estimates of $24.30 million. Trinity Biotech PLC had a return on equity of 3.03% and a net margin of 15.77%. On average, analysts forecast that Trinity Biotech PLC will post $0.14 EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Royce & Associates LP raised its position in shares of Trinity Biotech PLC by 13.7% in the first quarter. Royce & Associates LP now owns 799,098 shares of the company’s stock valued at $9,317,000 after buying an additional 96,500 shares during the last quarter. Kimelman & Baird LLC raised its position in shares of Trinity Biotech PLC by 0.6% in the first quarter. Kimelman & Baird LLC now owns 109,367 shares of the company’s stock valued at $1,275,000 after buying an additional 675 shares during the last quarter. Adirondack Research & Management Inc. raised its position in shares of Trinity Biotech PLC by 1.3% in the first quarter. Adirondack Research & Management Inc. now owns 415,353 shares of the company’s stock valued at $4,843,000 after buying an additional 5,466 shares during the last quarter. Bank of Montreal Can acquired a new position in shares of Trinity Biotech PLC during the second quarter valued at approximately $8,242,000. Finally, Emerald Acquisition Ltd. acquired a new position in shares of Trinity Biotech PLC during the second quarter valued at approximately $5,109,000. 71.14% of the stock is owned by institutional investors.
About Trinity Biotech PLC
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with MarketBeat.com's FREE daily email newsletter.